Innovative Bispecific Nanobody Targeting FAP and LTBR for Solid Tumor Therapy

VHH-P812 is a cutting-edge humanized bispecific nanobody designed to target both fibroblast activation protein alpha (FAP) and lymphotoxin beta receptor (LTBR), two well-validated therapeutic targets in oncology. Currently in the Biological Testing phase, VHH-P812 holds significant promise for the treatment of solid tumors. By simultaneously engaging FAP and LTBR, this novel molecule leverages the pathological roles of both targets within the tumor microenvironment. The dual-targeting approach aims to improve therapeutic efficacy and potentially overcome resistance mechanisms, positioning VHH-P812 as a strong candidate for future solid tumor therapies.

Licensing Opportunity

VHH-P812 is available for out-licensing and strategic collaborations. Partners interested in advancing solid tumor therapeutics are welcome to explore licensing or co-development opportunities for this promising bispecific nanobody platform.

Development Phase

Modality

VHH-P812 is a human bispecific antibody composed of a single-domain antibody directed against lymphotoxin-beta receptor and an antigen-binding fragment specific for fibroblast activation protein, both fused to a human Fc domain engineered for minimal Fc-gamma receptor interaction. This nanobody-based approach capitalizes on the small size and high stability of single-domain antibodies, which enables superior tissue penetration and rapid targeting within solid tumor environments. The minimized Fc-gamma binding reduces the likelihood of off-target immune activation. The modular format of VHH-P812 offers robust manufacturability and versatility for diverse solid tumor strategies.

Target

FAP and LTBR are key molecular targets in solid tumor biology. FAP is a cell-surface serine protease primarily expressed by cancer-associated fibroblasts, playing a crucial role in tumor progression, extracellular matrix remodeling, and immune evasion within the tumor stroma. LTBR is a member of the tumor necrosis factor receptor superfamily, mainly present on stromal cells, certain epithelial cells, and immune cells; it regulates immune responses and tissue organization. Aberrant expression of FAP and dysregulation of LTBR signaling are frequently observed in diverse solid tumors and are associated with poor prognosis. Dual targeting of FAP and LTBR addresses both tumor stroma and immune modulation, offering strategic value for disrupting the tumor microenvironment and potentiating anti-tumor immunity. The ability of VHH-P812 to engage both FAP and LTBR underlines its significant potential in solid tumor therapy development pipelines.

Mechanism of Action

VHH-P812 exerts its anti-tumor effects via the simultaneous engagement of FAP and LTBR. The molecule binds FAP, selectively expressed in cancer-associated fibroblasts, leading to disruption of tumor-supportive stroma. Concurrently, VHH-P812 acts as an agonist for LTBR, a key modulator of immune and stromal cell interaction in the tumor microenvironment. Through this dual mechanism—anti-FAP activity and LTBR agonism—VHH-P812 aims to remodel the tumor stroma and enhance anti-tumor immune signaling. The nanobody platform underpinning VHH-P812 supports advanced designs, including bispecific and multi-specific formats, and can be further developed for antibody-drug conjugates or other engineered biotherapeutics targeting solid tumors.

Solid Tumor

Solid tumors represent a highly prevalent and diverse group of malignancies, encompassing cancers of the lung, breast, colon, prostate, and many other organ systems. Globally, solid tumors account for a substantial proportion of cancer incidence and mortality. Current standard therapies include surgical resection, chemotherapy, radiation, immunotherapy, and targeted biological agents. Despite advancements, significant challenges remain, such as therapeutic resistance, tumor heterogeneity, and the immunosuppressive tumor microenvironment. Many patients with advanced or recurrent solid tumors have limited effective treatment options and face a poor prognosis. Novel therapeutic strategies that specifically target components of the tumor stroma and modulate immune responses, such as those enabled by VHH-P812's bispecific nanobody platform, have the potential to address these unmet needs. By disrupting tumor-promoting fibroblasts and enhancing immune activity, VHH-P812 offers a promising avenue for improving outcomes in solid tumor patients.